Diagnostic and therapeutic imaging for cancer: Therapeutic considerations and future directions

Roach, Mack; Albérini, Jean Louis; Pecking, A; Testori, Alessandro; Verrecchia, F.; Soteldo, Javier; Ganswindt, Ute; Joyal, John L.; Babich, John W.; Witte, Russell S.; Unger, Evan C.; Gottlieb, Ronald H.

doi:10.1002/jso.21805

Cited by 18 publications

(21 citation statements)

References 141 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ultrasound detection with contrast agents has been described to have picomolar sensitivity –on par with optical and nuclear imaging 2 , yet the small size of highly echogenic (ultrasound-visible) agents has been elusive. Discoveries aimed at development of robust contrast agent formulations, and appropriate hardware and software that overcome these challenges will serve as a springboard for a new application of ultrasound.…”

Section: Introductionmentioning

confidence: 99%

Ultrasound imaging beyond the vasculature with new generation contrast agents

Perera

Hernandez

Zhou

et al. 2015

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Current commercially available ultrasound contrast agents are gas-filled, lipid- or protein-stabilized microbubbles larger than 1 μm in diameter. Because the signal generated by these agents is highly dependent on their size, small yet highly echogenic particles have been historically difficult to produce. This has limited the molecular imaging applications of ultrasound to the blood pool. In the area of cancer imaging, microbubble applications have been constrained to imaging molecular signatures of tumor vasculature and drug delivery enabled by ultrasound-modulated bubble destruction. Recently, with the rise of sophisticated advancements in nanomedicine, ultrasound contrast agents, which are an order of magnitude smaller (100-500 nm) than their currently utilized counterparts, have been undergoing rapid development. These agents are poised to greatly expand the capabilities of ultrasound in the field of targeted cancer detection and therapy by taking advantage of the enhanced permeability and retention phenomenon of many tumors and can extravasate beyond the leaky tumor vasculature. Agent extravasation facilitates highly sensitive detection of cell surface or microenvironment biomarkers, which could advance early cancer detection. Likewise, when combined with appropriate therapeutic agents and ultrasound-mediated deployment on demand, directly at the tumor site, these nanoparticles have been shown to contribute to improved therapeutic outcomes. Ultrasound's safety profile, broad accessibility and relatively low cost make it an ideal modality for the changing face of healthcare today. Aided by the multifaceted nano-sized contrast agents and targeted theranostic moieties described herein, ultrasound can considerably broaden its reach in future applications focused on the diagnosis and staging of cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Ultrasound imaging beyond the vasculature with new generation contrast agents

Perera

Hernandez

Zhou

et al. 2015

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…If the lesion is operable, the orientation of the pancreas and its surrounding structures will guide planning a detailed strategy for the surgical intervention. Typically the decision and planning steps are based upon two dimensional (2D) medical images of the patient from a variety of sources including computed tomography (CT), magnetic resonance imaging, ultrasound, photoacoustic imaging, positron emission tomography (PET), and other optical imaging using fluorescence [39]. Planning for this delicate operation requires surgeons to translate the 2D image slices into a 3D mental picture of the patient's anatomy, which can be a difficult task.…”

Section: Discussionmentioning

confidence: 99%

Three Dimensional Projection Environment for Molecular Design and Surgical Simulation

Wickstrom

Chen²,

Devadhas³

et al. 2011

View full text Add to dashboard Cite

REPORT DOCUMENTATION PAGEForm Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS. (From -To) 29- 07-2009 -28-07-2011 REPORT DATE (DD-MM-YYYY) 28-08-2011 REPORT TYPE Final DATES COVERED SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S)Medical Research and Materiel USAMRMC Materiel Command TATRC Telemedicine & Advanced Fort Detrick SPONSOR/MONITOR'S REPORTTechnology Research Center Maryland 21702-5012 NUMBER(S) DISTRIBUTION / AVAILABILITY STATEMENTApproved for public release; distribution unlimited SUPPLEMENTARY NOTES ABSTRACTWe hypothesized in Aim 1 that docking of three-dimensional (3D) projections of potential target binding agents with 3D projections of macromolecular disease targets visualized on a computer with touch and feel feedback will enable identification of optimal agent designs, and culling of suboptimal agent designs, prior to synthesis. We found that direct measurements of cellular uptake of two different EGF fragments, EGF20-31 and EGF32-48, agreed with the computer predictions of no uptake by EGF20-31, and significant uptake by EGF32-48. This observation is consistent with our first hypothesis. We hypothesized in Aim 2 that 3D FDG PET images of patients superimposed on 3D anatomical images of patients visualized on a large computer display would enable improved preoperative planning, because the FDG PET images revealed specific sites of active disease. We found that a set of 6 experienced surgeons found that the final 3D version was accurate, useful, and worth applying in practice. This observation is consistent with our second hypothesis. SUBJECT TERMScancer, computerized tomography, haptic, hybridization, imaging, molecular dynamics, nuclear medicine, oncogene, pancreatic, positron emission tomography, receptors, surgery, volumetric A. INTRODUCTIONWe hypothesized that our fusion of genetic, visual, and tactile information would improve surgeons' understanding of the extent of disease and will ultimately permit surgeons to better plan operations and to prepare for the actual pathology found. We proposed to combine current medical imaging technologies with genetic imaging to leverage our ability to pr...

show abstract

“…The positive lymph nodes are marked and then surgically excised. RULL constitutes a possible refinement of the ''traditional'' SLN biopsy procedure [21].…”

Section: Radioguided Ultrasound-guided Lymph Node Localization (Rull)mentioning

confidence: 99%

Multimodal imaging in radioguided surgery

KleinJan

Bunschoten

Brouwer

et al. 2013

Clin Transl Imaging

View full text Add to dashboard Cite

Radioguided surgery (RGS) utilizes radiolabeled tracers that accumulate in the lesion of interest following local or systemic administration. RGS is an expanding surgical guidance technology, but unfortunately most currently available radiotracers are unable to provide intraoperative optical information regarding the location of the lesion. In 2011, a new hybrid tracer (both radioactive and fluorescent) was introduced for sentinel lymph node detection. This hybrid tracer (indocyanine green99m Tcnanocolloid) has helped to generate a new hybrid surgical guidance concept, thereby expanding the traditional RGSbased approach. Based on its radioactive signature a hybrid tracer is able to preserve the ''traditional'' role for RGS. Furthermore, as an additional tool in the operating room, a hybrid tracer provides optical information via fluorescence guidance. This review discusses the most common RGS approaches. Different clinically used radioactive tracers and their potential hybrid derivatives are also discussed. Furthermore, the various imaging devices designed for radioactivity-based detection are reviewed in the context of generating hybrid-imaging modalities.

show abstract

Diagnostic and therapeutic imaging for cancer: Therapeutic considerations and future directions

Cited by 18 publications

References 141 publications

Ultrasound imaging beyond the vasculature with new generation contrast agents

Ultrasound imaging beyond the vasculature with new generation contrast agents

Three Dimensional Projection Environment for Molecular Design and Surgical Simulation

Multimodal imaging in radioguided surgery

Contact Info

Product

Resources

About